The company was established in North America in United States. The main department of described VC is located in the Germany.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Definigen, evonetix, Phico Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most successful fund investment fields, there are Biopharma, Therapeutics.
Comparing to the other companies, this Providence Investment Company Limited performs on 19 percentage points less the average number of lead investments. Deals in the range of 1 - 5 millions dollars are the general things for fund. The high activity for fund was in 2013. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2014.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Providence Investment Company Limited, startups are often financed by UK Innovation & Science Seed Fund, Nesta Ventures, Morningside Venture Partners. The meaningful sponsors for the fund in investment in the same round are UK Innovation & Science Seed Fund, Morningside Venture Partners, Avlar BioVentures. In the next rounds fund is usually obtained by Morningside Venture Partners, Nesta Ventures, UK Innovation & Science Seed Fund.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
evonetix | $27M | 07 Feb 2023 | Uttlesford, England, United Kingdom | ||
evonetix | $30M | 02 Mar 2020 | Uttlesford, England, United Kingdom | ||
evonetix | $12M | 30 Jan 2018 | Uttlesford, England, United Kingdom | ||
Definigen | $2M | 23 May 2016 | Cambridge, England, United Kingdom | ||
Horizon Discovery | $15M | 13 Sep 2011 | Cambridge, England, United Kingdom | ||
CellCentric | 03 Jun 2004 | Cambridge, England, United Kingdom | |||
Phico Therapeutics | $616K | 01 Feb 2003 | Cambridge, England, United Kingdom | ||
Phico Therapeutics | 01 Sep 2000 | Cambridge, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
evonetix | $27M | 07 Feb 2023 | Uttlesford, England, United Kingdom | ||
evonetix | $30M | 02 Mar 2020 | Uttlesford, England, United Kingdom | ||
evonetix | $12M | 30 Jan 2018 | Uttlesford, England, United Kingdom | ||
Definigen | $2M | 23 May 2016 | Cambridge, England, United Kingdom | ||
Horizon Discovery | $15M | 13 Sep 2011 | Cambridge, England, United Kingdom | ||
CellCentric | 03 Jun 2004 | Cambridge, England, United Kingdom | |||
Phico Therapeutics | $616K | 01 Feb 2003 | Cambridge, England, United Kingdom | ||
Phico Therapeutics | 01 Sep 2000 | Cambridge, England, United Kingdom |